Screening Program for Early Detection of Pancreatic Cancer
(AI-PACED Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This clinical trial studies a new screening program to improve the early detection of sporadic pancreatic cancer in individuals with a high risk of developing pancreatic cancer. Pancreatic cancer remains one of the deadliest solid tumors, characterized by a long phase without symptoms followed by rapid progression once clinically evident. Despite advancements in treatment, the survival rate for pancreatic cancer remains low. Research has helped to identify a subset of individuals with a markedly high short-term risk for developing pancreatic cancer, which includes adults aged 50 and older with glycemically-defined new-onset diabetes and an Enriching New-Onset Diabetes for Pancreatic Cancer (ENDPAC) score ≥ 3. However, current practice guidelines do not provide clear pathways for surveillance or early detection. The screening program in this trial combines repeated contrast-enhanced computed tomography (CT) scans using artificial intelligence (AI) and blood draws. Contrast-enhanced CT is an imaging technique which creates a series of detailed pictures of areas inside the body; the pictures are created by a computer linked to an x-ray machine and a contrast agent is used to enhance the images. The images are then reviewed using AI, which may make it easier to spot cancer earlier on the CT scans than with the human eye. Studying samples of blood in the laboratory from high-risk individuals may help doctors understand more about why they may develop pancreatic cancer. This may be an effective way to screen high-risk individuals and improve the early detection of sporadic pancreatic cancer.
Who Is on the Research Team?
Ajit H. Goenka, MD
Principal Investigator
Mayo Clinic in Rochester
Are You a Good Fit for This Trial?
This trial is for adults aged 50-85 with a high risk of pancreatic cancer, indicated by new-onset diabetes and an ENDPAC score ≥ 3. Participants must consent to the study's procedures.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo baseline contrast-enhanced abdominal CT and blood sample collection
Surveillance
Participants undergo contrast-enhanced CT and blood sample collection at 6 and 12 months, with EMR surveillance for PDA diagnosis
Extended Follow-up
Participants continue EMR surveillance for PDA diagnosis
Follow-up
Participants are monitored for safety and effectiveness after the main surveillance period
What Are the Treatments Tested in This Trial?
Interventions
- Biospecimen Collection
- Computed Tomography with Contrast
Trial Overview
The trial tests a screening program using AI-enhanced CT scans and blood tests to detect sporadic pancreatic cancer early in high-risk individuals.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
Patients undergo blood sample collection at baseline, 6 months, and 12 months in the absence of unacceptable toxicity. Patients also undergo EMR surveillance for PDA diagnosis for up to 36 months.
Patients undergo contrast-enhanced abdominal CT and blood sample collection at baseline, 6 months, and 12 months in the absence of unacceptable toxicity. Patients also undergo EMR surveillance for PDA diagnosis for up to 36 months.
Patients undergo EMR surveillance for PDA diagnosis for up to 36 months.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.